Patents by Inventor Linghua Meng

Linghua Meng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11214572
    Abstract: The present disclosure relates to 7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof. These compounds show good PI3K inhibitory activity, can effectively inhibit the activity of PI3K kinase, and has significant enhancement and improvement of pharmacokinetic properties, such as bioavailability, due to the introduction of the 7-position group; furthermore, the compounds of the present disclosure exhibit an unpredictable high selectivity and strong inhibitory activity on PI3K?, and thus these compounds can be used for treating diseases related to PI3K pathway, especially for anti-cancer or for the treatment of tumors, leukemias and autoimmune diseases. After further optimizing and screening, the compounds are expected to be developed into a new type of anti-tumor drugs.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: January 4, 2022
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Chunhao Yang, Linghua Meng, Haoyue Xiang, Jing Li, Xi Zhang, Xiang Wang, Cun Tan, Qian He, Jian Ding, Yi Chen
  • Publication number: 20200157110
    Abstract: The present disclosure relates to 7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof. These compounds show good PI3K inhibitory activity, can effectively inhibit the activity of PI3K kinase, and has significant enhancement and improvement of pharmacokinetic properties, such as bioavailability, due to the introduction of the 7-position group; furthermore, the compounds of the present disclosure exhibit an unpredictable high selectivity and strong inhibitory activity on PI3K?, and thus these compounds can be used for treating diseases related to PI3K pathway, especially for anti-cancer or for the treatment of tumors, leukemias and autoimmune diseases. After further optimizing and screening, the compounds are expected to be developed into a new type of anti-tumor drugs.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 21, 2020
    Inventors: Chunhao YANG, Linghua MENG, Haoyue XIANG, Jing LI, Xi ZHANG, Xiang WANG, Cun TAN, Qian HE, Jian DING, Yi CHEN
  • Patent number: 10328060
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: November 1, 2015
    Date of Patent: June 25, 2019
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Xingdong Zhao, Jian Ding, Linghua Meng, Meiyu Geng, Tongshuang Li, Zuwen Zhou, Ling Chen, Qihong Liu, Xianlong Wang, Lijun Yang, Yue Rong, Rui Tan, Chuiliang Yu, Lihua Jiang, Yanxin Liu, Li Linghu, Jing Sun, Weibo Wang
  • Publication number: 20180036293
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Application
    Filed: November 1, 2015
    Publication date: February 8, 2018
    Applicants: Shanghai Fochon Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica Chinese Academy of Sciences, ChongQing Fochon Pharmaceutical Co., Ltd.
    Inventors: Xingdong ZHAO, Jian DING, Linghua MENG, Meiyu GENG, Tongshuang LI, Zuwen ZHOU, Ling CHEN, Qihong LIU, Xianlong WANG, Lijun YANG, Yue RONG, Rui TAN, Chuiliang YU, Lihua JIANG, Yanxin LIU, Li LINGHU, Jing SUN, Weibo WANG
  • Patent number: 9724352
    Abstract: The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 8, 2017
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Haihe Pharmaceutical Co., Ltd.
    Inventors: Chunhao Yang, Linghua Meng, Yanhong Chen, Xiang Wang, Cun Tan, Jiapeng Li, Jian Ding, Yi Chen
  • Publication number: 20170000800
    Abstract: The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
    Type: Application
    Filed: September 19, 2016
    Publication date: January 5, 2017
    Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Haihe Pharmaceutical Co., Ltd.
    Inventors: CHUNHAO YANG, Linghua Meng, Yanhong Chen, Xiang Wang, Cun Tan, Jiapeng Li, Jian Ding, Yi Chen
  • Patent number: 9447101
    Abstract: The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: September 20, 2016
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Haihe Pharmaceutical Co., Ltd.
    Inventors: Chunhao Yang, Linghua Meng, Yanhong Chen, Xiang Wang, Cun Tan, Jiapeng Li, Jian Ding, Yi Chen
  • Patent number: 9216962
    Abstract: The present invention relates to thiazole compounds of formula I, the method for preparation and use thereof. More specifically, the present invention relates to novel derivatives of natural product largazole, the method for preparing them and their uses for treatments against tumor and multiple sclerosis as inhibitors of histone deacetylase.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: December 22, 2015
    Assignee: Shanghai Puyi Chemical Co., Ltd.
    Inventors: Fajun Nan, Fei Chen, Yangming Zhang, Jia Li, Yubo Zhou, Mingbo Su, Jian Ding, Linghua Meng, Xin Xie, Shixian Wang
  • Publication number: 20150141644
    Abstract: The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.
    Type: Application
    Filed: April 23, 2013
    Publication date: May 21, 2015
    Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Haihe Pharmaceutical Co., Ltd.
    Inventors: Chunhao Yang, Linghua Meng, Yanhong Chen, Xiang Wang, Cun Tan, Jiapeng Li, Jian Ding, Yi Chen
  • Publication number: 20140148600
    Abstract: The present invention relates to thiazole compounds of formula I, the method for preparation and use thereof. More specifically, the present invention relates to novel derivatives of natural product largazole, the method for preparing them and their uses for treatments against tumor and multiple sclerosis as inhibitors of histone deacetylase.
    Type: Application
    Filed: May 7, 2012
    Publication date: May 29, 2014
    Inventors: Fajun Nan, Fei Chen, Yangming Zhang, Jia Li, Yubo Zhou, Mingbo Su, Jian DING, Linghua Meng, Xin Xie, Shixian Wang
  • Patent number: 8455510
    Abstract: Rapalogs of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and preparation methods and uses thereof. The rapalogs have the structure of formula I and can be used as an anti-tumor medicament. Comparing with rapamycin, the rapalogs of the present invention exhibit enhanced water solubility, and improved pharmacological and pharmacokinetic properties by introducing a hydrophilic and polar group such as a hydroxyl.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: June 4, 2013
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jian Ding, Jianping Zuo, Linqian Yu, Linghua Meng, Yangming Zhang, Na Yang, Min Gu
  • Publication number: 20110166172
    Abstract: Rapalogs of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and preparation methods and uses thereof. The rapalogs have the structure of formula I and can be used as an anti-tumor medicament. Comparing with rapamycin, the rapalogs of the present invention exhibit enhanced water solubility, and improved pharmacological and pharmacokinetic properties by introducing a hydrophilic and polar group such as a hydroxyl.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 7, 2011
    Applicant: Shanghai institute of Materia Medica, chinese Academy of Sciences
    Inventors: Fajun Nan, Jian Ding, Jianping Zuo, Linqian Yu, Linghua Meng, Yangming Zhang, Na Yang, Min Gu